Alpha Tau Medical Plans Engaging Investor Meetings in September
Alpha Tau Medical's Upcoming Investor Engagements
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) is making waves in the oncology sector with its cutting-edge approach to cancer treatment. Recently, the Chief Financial Officer, Raphi Levy, announced an exciting schedule for September, where the company will actively engage with investors at five significant conferences. This initiative underscores Alpha Tau's commitment to transparency and investor relations as it advances its pioneering cancer therapy, Alpha DaRT.
Innovative Technology: Alpha DaRT
At the heart of Alpha Tau Medical's offerings is the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). This novel cancer treatment utilizes localized alpha particle radiotherapy aimed at effectively targeting and destroying solid tumors. The treatment is designed to minimize damage to the surrounding healthy tissue, representing a significant advancement in cancer care.
What makes Alpha DaRT particularly unique is its ability to engage the body’s immune system. Preliminary studies have shown promising immuno-stimulatory effects, which could enhance the efficacy of other treatment modalities. Alpha Tau Medical is currently exploring the combined use of Alpha DaRT with other existing therapies, opening new avenues in the battle against cancer.
Details of Investor Conferences
To facilitate deeper communication with investors, Alpha Tau will participate in multiple conferences this September:
- Citi 2025 Biopharma Back to School Summit
Format: 1x1 Meetings
Date: September 2-3, 2025
Location: Boston, MA - H.C. Wainwright 27th Annual Global Investment Conference
Format: Company Presentation and 1x1 Meetings
Date: September 9, 2025
Time: 3:00 - 3:30pm
Location: New York, NY - Oppenheimer’s Third Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Format: 1x1 Meetings
Date: September 11, 2025
Location: New York, NY - RTH & Co / Redburn Atlantic - Radiopharma Landscape Conference
Format: 1x1 Meetings
Date: September 26, 2025
Location: New York, NY - Lytham Partners Fall 2025 Investor Conference
Format: 1x1 Meetings
Date: September 30, 2025
Location: Virtual
Mr. Levy will be available for one-on-one meetings during these events, encouraging interested parties to connect with their conference representatives to schedule discussions.
About Alpha DaRT Technology
Alpha DaRT focuses on delivering radium-224 directly to solid tumors, ensuring targeted radiation that primarily affects the cancer cells while preserving nearby healthy tissues. Due to its short-range alpha-emitters, this innovative therapy seeks to minimize side effects associated with traditional radiation treatments.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau Medical Ltd. is at the forefront of oncology therapeutics, dedicated to the research, development, and commercialization of its advanced Alpha DaRT technology. The ground-breaking therapeutic approach was developed by esteemed researchers, Professors Itzhak Kelson and Yona Keisari, at Tel Aviv University, reflecting a strong commitment to scientific advancement in cancer treatment.
As Alpha Tau Medical continues to explore its technology's potential through various clinical trials, key milestones and significant data are expected in the near future, reinforcing their position in the oncology market.
Frequently Asked Questions
What is Alpha DaRT?
Alpha DaRT is a novel cancer treatment that utilizes localized alpha particle radiotherapy aimed at targeting and destroying solid tumors while minimizing harm to healthy tissues.
Who is presenting at the conferences?
Raphi Levy, the CFO of Alpha Tau Medical, will be representing the company at the upcoming investor conferences.
When is the next investor conference for Alpha Tau?
The next conference is the Citi 2025 Biopharma Back to School Summit, scheduled for September 2-3, 2025.
How does Alpha DaRT differ from traditional therapies?
Alpha DaRT specifically targets tumor cells using localized alpha radiation and is designed to protect surrounding healthy tissues, resulting in potentially fewer side effects compared to traditional radiation methods.
Where can I get more information about Alpha Tau Medical?
For more information, you can reach out to their investor relations at IR@alphatau.com.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.